• Moderna will present initial Phase 1/2 mRNA-2808 trial results at the American Society of Hematology meeting on December 12, 2026.
• The investigational therapy produced responses in heavily pretreated patients with relapsed or refractory multiple myeloma, including some previously treated with targeted therapies.
• No dose-limiting toxicities or treatment-related serious adverse events occurred, though severe treatment-related side effects were predominantly blood-related.
• Updated results from the ongoing MyEngage trial are expected at the meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611040950ACCESSWRNAPR_____1245962) on November 04, 2026, and is solely responsible for the information contained therein.